琥珀酸他舒格替尼的功效与作用

Tasugatinib succinate is a targeted therapy drug developed by Eisai Co., Ltd. of Japan. It is mainly used to treat patients with unresectable biliary tract cancer carrying FGFR2 gene fusion or rearrangement. The drug effectively blocks the growth signals of tumor cells by inhibiting FGFR1, FGFR2 and FGFR3 targets. Although it has not yet been launched in China, its successful approval in Japan shows its potential in the treatment of biliary tract cancer.

The efficacy and role of tasugatinib succinate

It is a targeted therapy drug for patients with biliary tract cancer with specific gene mutations. Its unique mechanism and significant efficacy make it an important choice in this field.

Targeted inhibition of the FGFR signaling pathway

Tasugatinib succinate blocks the proliferation and survival signals of tumor cells by selectively inhibiting the activities of FGFR1, FGFR2 and FGFR3. This precise mechanism of action makes it effective in delaying tumor progression, especially for patients whose disease has worsened after chemotherapy.

Significant clinical efficacy

In clinical trials conducted in Japan, tasugatinib succinate showed significant efficacy in patients with biliary tract cancer carrying FGFR2 gene abnormalities. It can extend the patients' progression-free survival and improve their quality of life.

Dosage Form and Usage

The drug is a yellow film-coated tablet, each containing 35 mg of active ingredient. The recommended dose is 140 mg once daily, taken on an empty stomach. Doctors will adjust the dose according to the patient's specific condition to ensure maximum therapeutic effect.

The development of tasugatinib succinate provides new treatment hope for patients with biliary tract cancer. Its targeting and high efficiency make it an important choice for the treatment of biliary tract cancer in the future.

Usage of tasugatinib succinate in special groups

Different groups of people may have different responses to the drug, so the use of tasugatinib succinate in special groups needs to be done with extreme caution.

Pregnant and lactating women

Use in pregnant women or women who may become pregnant should only be considered if the benefits of treatment significantly outweigh the potential risks. Breastfeeding women should avoid using this drug to prevent the drug from passing through breast milk and causing harm to the baby.

Children and patients with hepatic impairment

The safety and effectiveness of tasugatinib succinate in children has not yet been determined, and relevant clinical trial data are currently lacking. Caution is advised in patients with impaired hepatic function, and dose adjustments may be necessary to avoid excessive drug concentrations.

Population of reproductive potential

Men and women of childbearing potential need to take strict contraceptive measures during use and after stopping the drug. Female patients should use contraception for at least 6 days after the last dose, and male patients should use barrier methods of contraception.

Medications for special groups must be taken under the guidance of a doctor to reduce potential risks.

Contraindications of tasugatinib succinate

Tasugatinib succinate is not suitable for all patients, and its use may be prohibited in certain circumstances.

Severe hyperphosphatemia

This drug may cause hyperphosphatemia. If the serum phosphorus concentration continues to increase and cannot be controlled by diet or drugs, the drug needs to be discontinued immediately.

Retinal disease

Patients may develop retinal detachment or other serious eye problems. If intolerable grade 2 or 3 corneal disease occurs, the drug needs to be discontinued until the symptoms are relieved; for grade 4 symptoms, the drug needs to be permanently discontinued.

Abnormalities of the blood system

Grade 3 or 4 hematological diseases (such as thrombocytopenia, neutropenia) need to suspend the medication, and reduce the dosage and resume or permanently discontinue the medication after the symptoms are relieved.

Patients should understand the contraindications in advance and strictly follow the medication instructions, and review them regularly during medication.